Skip to main content Accessibility help
Hostname: page-component-56f9d74cfd-hg4f7 Total loading time: 0.78 Render date: 2022-06-26T00:16:56.399Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

16 - Aripiprazole, Aripiprazole Monohydrate, and Aripiprazole Lauroxil

Published online by Cambridge University Press:  19 October 2021

Jonathan M. Meyer
University of California, San Diego
Stephen M. Stahl
University of California, Riverside and San Diego
Get access


Aripiprazole has been available since 2002, with long-acting injectable versions approved in 2013 and 2015. Aside from clozapine, all antipsychotics approved prior to aripiprazole acted principally via postsynaptic dopamine D2 receptor antagonism in the associative striatum [2, 3]. While D2 antagonist antipsychotics are very useful, excessively high levels of striatal D2 occupancy (i.e. >> 80% reduction in the postsynaptic dopamine signal) resulted in higher rates of adverse neurological effects (e.g. parkinsonism, akathisia), subjective complaints of dysphoria or decreased well-being, and occasionally symptomatic worsening [4, 5].

The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 318 - 336
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Sparshatt, A., Taylor, D., Patel, M. X., et al. (2010). A systematic review of aripiprazole – dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry, 71, 14471556.
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., et al. (2010). Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry, 67, 231239.
Kim, J. H., Son, Y. D., Kim, H. K., et al. (2011). Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride. J Clin Psychopharmacol, 31, 507511.
Van Putten, T., Marder, S. R., Mintz, J., et al. (1992). Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry, 149, 500505.
Veselinovicć, T., Scharpenberg, M., Heinze, M., et al. (2019). Dopamine D2 receptor occupancy estimated from plasma concentrations of four different antipsychotics and the subjective experience of physical and mental well-being in schizophrenia: results from the randomized NeSSy Trial. J Clin Psychopharmacol, 39, 550560.
Burris, K. D., Molski, T. F., Xu, C., et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther, 302, 381389.
Tadori, Y., Forbes, R. A., McQuade, R. D., et al. (2011). In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol, 668, 355365.
Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Chicago, IL: McGraw-Hill, pp. 279302.
Takeuchi, H. and Remington, G. (2013). A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology (Berl), 228, 175185.
Kane, J. M., Correll, C. U., Goff, D. C., et al. (2009). A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry, 70, 13481357.
Cipriani, A., Accordini, S., Nose, M., et al. (2013). Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. J Clin Psychopharmacol, 33, 533537.
Meyer, J. M. and Stahl, S. M. (2019). The Clozapine Handbook. Cambridge: Cambridge University Press.
Girgis, R. R., Slifstein, M., D’Souza, D., et al. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl), 233, 35033512.
Stahl, S. M. (2017). Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr, 22, 375384.
Stroup, T. S., McEvoy, J. P., Ring, K. D., et al. (2011). A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry, 168, 947956.
Kirschbaum, K. M., Müller, M. J., Malevani, J., et al. (2008). Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry, 9, 212218.
Lin, S. K., Chen, C. K., and Liu, Y. L. (2011). Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia. J Clin Psychopharmacol, 31, 758762.
Yokoi, F., Grunder, G., Biziere, K., et al. (2002). Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology, 27, 248259.
Mamo, D., Graff, A., Mizrahi, R., et al. (2007). Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry, 164, 14111417.
Grunder, G., Fellows, C., Janouschek, H., et al. (2008). Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry, 165, 988995.
Kegeles, L. S., Slifstein, M., Frankle, W. G., et al. (2008). Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology, 33, 31113125.
Mizrahi, R., Mamo, D., Rusjan, P., et al. (2009). The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int J Neuropsychopharmacol, 12, 715721.
Takahata, K., Ito, H., Takano, H., et al. (2012). Striatal and extrastriatal dopamine D2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [C]raclopride and [C]FLB457. Psychopharmacology, 222, 165172.
Kurose, S., Mimura, Y., Uchida, H., et al. (2020). Dissociation in pharmacokinetic attenuation between central dopamine D2 receptor occupancy and peripheral blood concentration of antipsychotics: a systematic review. J Clin Psychiatry, 81, 19r13113.
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81,
Otsuka America Pharmaceutical Inc. (2020). Abilify package insert. Rockville, MD.
Nemoto, K., Mihara, K., Nakamura, A., et al. (2012). Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit, 34, 188192.
Suzuki, T., Mihara, K., Nakamura, A., et al. (2014). Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit, 36, 651655.
Meyer, J. M. (2017). Converting oral to long acting injectable antipsychotics: a guide for the perplexed. CNS Spectr, 22, 1428.
Otsuka America Pharmaceutical Inc. (2020). Abilify Maintena package insert. Rockville, MD.
Alkermes Inc. (2020). Aristada package insert. Walltham, MA.
Alkermes Inc. (2020). Aristada Initio package insert. Walltham, MA.
Hard, M. L., Mills, R. J., Sadler, B. M., et al. (2017). Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol, 37, 289295.
Hard, M. L., Mills, R. J., Sadler, B. M., et al. (2017). Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model. CNS Drugs, 31, 617624.
Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.
Jain, R., Meyer, J. M., Wehr, A. Y., et al. (2020). Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia. CNS Spectr, 25, 323330.
Meltzer, H. Y., Risinger, R., Nasrallah, H. A., et al. (2015). A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry, 76, 10851090.
Potkin, S. G., Saha, A. R., Kujawa, M. J., et al. (2003). Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry, 60, 681690.
Saha, A., Ali, M. W., lngenito, G. G., et al. (2002). P.4.E.026 – Safety and tolerability of aripiprazole at doses higher than 30 mg (abstract from the XXIII CINP Congress, Montréal, June 23–27, 2002). Int J Neuropsychopharmacol, 5, S185.
Christensen, A. P., Boegevig, S., Christensen, M. B., et al. (2018). Overdoses with aripiprazole: signs, symptoms and outcome in 239 exposures reported to the Danish Poison Information Centre. Basic Clin Pharmacol Toxicol, 122, 293298.
Chavez, B. and Poveda, R. A. (2006). Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances. Ann Pharmacother, 40, 22652268.

Save book to Kindle

To save this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the or variations. ‘’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats